Anti-Rheumatic Drugs - Japan | Statista Market Forecast

In Japan, the revenue in the Anti-Rheumatic Drugs market is forecasted to reach US$1.16bn in 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2029) of 0.70%, which would lead to a market volume of US$1.20bn by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with an estimated US$34.70bn in 2024.
In Japan, the market for Anti-Rheumatic Drugs is experiencing an increased demand due to the aging population and a growing prevalence of rheumatic diseases.

Definition:
The market Anti-Rheumatic Drugs includes medication for the treatment of the inflammatory disease rheumatism. Due to the high prevalence of rheumatism and the large size of the market, this section of immune diseases is treated as a separate market. Both steroidal and non-steroidal anti-rheumatics are included. Disease-modifying rheumatic drugs (DMARDs), such as tumor necrosis factor inhibitors (a type of biologic DMARD), are particularly important in terms of commerciality.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: AbbVie, Johnson & Johnson, Pfizer, Amgen, Roche

Drugs to treat rheumatism
Steroidal (corticosteroids) and non-steroidal anti-rheumatics
Disease-modifying antirheumatic drugs (DMARDs)
Tumor necrosis factor (TNF) inhibitors

Drugs to treat other autoimmune diseases (such as multiple sclerosis or psoriasis)
Analgetics for general use (such as paracetamol)
Treatment of osteoarthritis

The Anti-Rheumatic Drugs market in Japan has been experiencing significant growth in recent years, driven by several factors.

Customer preferences: Patients suffering from rheumatoid arthritis and other related diseases in Japan have been increasingly seeking treatment options that provide long-term relief from pain and inflammation. As a result, there has been a growing demand for Anti-Rheumatic Drugs that offer sustained efficacy without significant side effects.

Trends in the market: One of the key trends in the Anti-Rheumatic Drugs market in Japan has been the increasing adoption of biologic drugs, which are derived from living organisms and target specific proteins that cause inflammation. These drugs have been shown to be highly effective in controlling symptoms and preventing joint damage, leading to a shift away from traditional disease-modifying antirheumatic drugs (DMARDs).Another trend in the market has been the development of novel therapies that target different pathways in the immune system. For example, Janus kinase (JAK) inhibitors have emerged as a promising class of drugs that can block the signaling pathways that lead to inflammation, offering a new treatment option for patients who have not responded to other therapies.

Local special circumstances: In Japan, there are strict regulations governing the approval and reimbursement of drugs, which can make it challenging for pharmaceutical companies to bring new therapies to market. However, the government has been taking steps to streamline the approval process and increase access to innovative treatments, which has created new opportunities for companies operating in the Anti-Rheumatic Drugs market.

Underlying macroeconomic factors: The aging population in Japan has also been a driver of growth in the Anti-Rheumatic Drugs market, as the prevalence of rheumatoid arthritis and related diseases increases with age. In addition, the government has been investing heavily in healthcare infrastructure and research, creating a favorable environment for pharmaceutical companies operating in the country.Overall, the Anti-Rheumatic Drugs market in Japan is expected to continue growing in the coming years, driven by the increasing adoption of biologic drugs and the development of novel therapies that offer new treatment options for patients. However, companies operating in the market will need to navigate the complex regulatory environment and demonstrate the safety and efficacy of their products to succeed in this highly competitive space.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The pharmaceutical industry is responsible for the research, development, production, and distribution of medications. The market has experienced significant growth during the past two decades, and pharma revenues worldwide totaled 1.48 trillion U.S. dollars in 2022.